XTL Biopharmaceuticals Ltd. (XTLB)
NASDAQ: XTLB · Real-Time Price · USD
2.910
+0.020 (0.69%)
Jul 10, 2026, 4:00 PM EDT - Market closed
Company Description
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel.
The company’s lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren’s syndrome.
It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications.
The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995.
XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Herzliya, Israel.
XTL Biopharmaceuticals Ltd.
| Country | Israel |
| Founded | 1993 |
| IPO Date | Sep 1, 2005 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 5 |
| CEO | Noam Band |
Contact Details
Address: 85 Medinat Hayehudim St. Herzliya, 4676670 Israel | |
| Phone | 972 5 4228 8897 |
| Website | xtlbio.com |
Stock Details
| Ticker Symbol | XTLB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001696804 |
| CUSIP Number | 98386D406 |
| ISIN Number | US98386D4060 |
Key Executives
| Name | Position |
|---|---|
| Noam Band | Chief Executive Officer and Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 17, 2026 | 424B3 | Prospectus |
| Dec 23, 2025 | 424B3 | Prospectus |
| Dec 15, 2025 | 424B3 | Prospectus |
| Feb 8, 2017 | 424B3 | Prospectus |